Evaluation of Choroidal Hemangioma and Treatment With Photodynamic Therapy by Using Enhanced Depth Imaging Optical Coherence Tomography

Ophthalmic Surg Lasers Imaging Retina. 2018 Mar 1;49(3):171-178. doi: 10.3928/23258160-20180221-04.

Abstract

Background and objective: To evaluate enhanced depth imaging optical coherence tomography (EDI-OCT) features of choroidal hemangioma and changes following photodynamic therapy (PDT).

Patients and methods: Retrospective review of 21 choroidal hemangiomas.

Results: On EDI-OCT, choroidal hemangioma showed low internal reflectivity in 47% of lesions and high internal reflectivity in 53%. The most common associated features were normal-looking honeycomb-like pattern in choriocapillaris in all lesions, inner segment/outer segment abnormality in 62%, photoreceptor outer segment abnormality in 62%, subretinal fluid with speckles in 62%, and shaggy photoreceptors in 57% of lesions. Internal reflectivity changed from low to high in 67% of lesions. Photoreceptor outer segment and plexiform layer abnormalities became more noticeable and shaggy photoreceptors improved.

Conclusion: On EDI-OCT, choroidal hemangioma showed normal-looking honeycomb-like pattern in the choriocapillaris, subretinal fluid with speckles, and abnormalities in the photoreceptor outer segment and plexiform layers. Following PDT, the choriocapillaris became sclerotic, and photoreceptor outer segment layer abnormalities were prominent. [Ophthalmic Surg Lasers Imaging Retina. 2018;49:171-178.].

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Child
  • Choroid / pathology*
  • Choroid Neoplasms / diagnosis*
  • Choroid Neoplasms / drug therapy
  • Female
  • Follow-Up Studies
  • Hemangioma / diagnosis*
  • Hemangioma / drug therapy
  • Humans
  • Male
  • Middle Aged
  • Photochemotherapy / methods*
  • Photosensitizing Agents / therapeutic use
  • Retrospective Studies
  • Tomography, Optical Coherence / methods*
  • Treatment Outcome
  • Verteporfin / therapeutic use*
  • Young Adult

Substances

  • Photosensitizing Agents
  • Verteporfin